Next Article in Journal
Concurrent Chemoradiotherapy for Locally Advanced Breast Cancer—Time for a New Paradigm?
Previous Article in Journal
Yoga in Adult Cancer: A Pilot Survey of Attitudes and Beliefs among Oncologists
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 1
10.3747/co.22.2178
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Serum C-Reactive Protein Predicts Poor Prognosis in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy

by
Y.C. Zeng
1,*,
R. Wu
1,*,
Y.P. Xiao
2,
F. Chi
1,
M. Xue
3,
Z.Y. Zhang
1,
R. Xing
1,
W.Z. Zhong
4,
S.L. Wang
1,
X. Tian
1,
W. Chen
1,
J.J. Chen
1 and
L.N. Wu
1
1
Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, China
2
Cancer Insititute, No. 1 Hospital of China Medical University, Shenyang, China
3
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China
4
Lung Cancer Research Institute and Cancer Center, Guangdong Provincial People’s Hospital, Guangzhou, China
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(1), 20-24; https://doi.org/10.3747/co.22.2178
Submission received: 4 November 2014 / Revised: 2 December 2014 / Accepted: 9 January 2015 / Published: 10 February 2015

Abstract

Background: We aimed to evaluate the association of serum C-reactive protein (crp) with prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Methods: We retrospectively reviewed 79 patients with locoregionally advanced nasopharyngeal carcinoma (cT3–4N0–3M0) treated with chemoradiotherapy. Chemoradiotherapy consisted of external-beam radiotherapy to the nasopharynx (70–80 Gy), the lymph node–positive area (60–70 Gy), and the lymph node–negative area (50–60 Gy) combined with 3 cycles of various platinum-based regimens delivered at 3-week intervals. Elevated crp was defined as more than 8 mg/L. The survival rate was calculated using the Kaplan–Meier method, and univariate and multivariate analyses (Cox proportional hazards model) were used to identify factors significantly associated with prognosis. Results: During the median follow-up of 3.9 years (range: 1–5.5 years), 23 patients died from nasopharyngeal cancer. The 5-year cancer-specific survival (css) rate was 62.90%. Before chemoradiotherapy, 18 patients had high serum crp; the css rate in that subgroup was significantly worse than the rate in the remaining patients (p = 0.0002). Multivariate analysis showed that crp was an independent prognostic indicator of css, with a hazard ratio of 3.04 (95% confidence interval: 1.22 to 7.55; p = 0.017). Among the 18 patients with elevated serum crp, 9 achieved normal serum crp after chemoradiotherapy, of whom 5 remained living with no evidence of recurrence or metastasis during follow-up. By contrast, the remaining 9 patients in whom serum crp did not normalize after chemoradiotherapy died within 4.2 years. Conclusions: Elevated serum crp before treatment predicts poor prognosis in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
Keywords: nasopharyngeal carcinoma; C-reactive protein; chemoradiotherapy; cancer-specific survival nasopharyngeal carcinoma; C-reactive protein; chemoradiotherapy; cancer-specific survival

Share and Cite

MDPI and ACS Style

Zeng, Y.C.; Wu, R.; Xiao, Y.P.; Chi, F.; Xue, M.; Zhang, Z.Y.; Xing, R.; Zhong, W.Z.; Wang, S.L.; Tian, X.; et al. Serum C-Reactive Protein Predicts Poor Prognosis in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy. Curr. Oncol. 2015, 22, 20-24. https://doi.org/10.3747/co.22.2178

AMA Style

Zeng YC, Wu R, Xiao YP, Chi F, Xue M, Zhang ZY, Xing R, Zhong WZ, Wang SL, Tian X, et al. Serum C-Reactive Protein Predicts Poor Prognosis in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy. Current Oncology. 2015; 22(1):20-24. https://doi.org/10.3747/co.22.2178

Chicago/Turabian Style

Zeng, Y.C., R. Wu, Y.P. Xiao, F. Chi, M. Xue, Z.Y. Zhang, R. Xing, W.Z. Zhong, S.L. Wang, X. Tian, and et al. 2015. "Serum C-Reactive Protein Predicts Poor Prognosis in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy" Current Oncology 22, no. 1: 20-24. https://doi.org/10.3747/co.22.2178

APA Style

Zeng, Y. C., Wu, R., Xiao, Y. P., Chi, F., Xue, M., Zhang, Z. Y., Xing, R., Zhong, W. Z., Wang, S. L., Tian, X., Chen, W., Chen, J. J., & Wu, L. N. (2015). Serum C-Reactive Protein Predicts Poor Prognosis in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy. Current Oncology, 22(1), 20-24. https://doi.org/10.3747/co.22.2178

Article Metrics

Back to TopTop